FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562798150> ?p ?o ?g. }

• W2562798150 abstract "Abstract Abstract 3253 Poster Board III-1 Chronic myelogenous leukemia (CML) is a hematopoietic stem cell (HSC) malignancy induced by p210-BCR-ABL and is characterized by myeloproliferation in the bone marrow (BM) and egress of leukemic stem cells and progenitors (LSC/P) to extramedullary sites. Persistence of BCR-ABL+ HSCs in patients under imatinib suggests that inhibition of ABL-kinase alone is not sufficient to completely eliminate the LSC/P population. Rac GTPases represent integrative molecular switches for p210-BCR-ABL-induced HSC transformation and combined pharmacological and genetic attenuation of Rac GTPases significantly prolong survival in vivo, as reported in a retroviral transduction/transplantation model (Thomas EK & Cancelas JA et al, Cancer Cell 2008). Here, we analyzed the role of Rac2 GTPase in the leukemic maintenance and in the interaction of LSC/P with the leukemic microenvironment in vivo. We used a stem cell leukemia (Scl) promoter-driven, tet-off, Scl-tTA x TRE-BCR-ABL (Scl/p210-BCR-ABL) binary transgenic mouse model (Koschmieder S et al., Blood 2005), where expression of BCR-ABL is restricted to the HSC/P compartment, allowing the study of the intrinsic molecular changes in LSC/P during leukemogenesis. In these mice, Scl-driven expression of BCR-ABL is active in HSC (Lin-/Sca1+/c-kit+; LSK) and progenitors (Lin-/c-kit+/Sca-1-; LK), and CML development is associated with the activation of downstream signaling effectors CrkL, p38-MAPK and JNK. Additionally, Scl/p210-BCR-ABL mice had increased cycling of LSK cells and expansion of circulating and splenic, but not BM, LSC/P, suggesting egress of LSC/Ps from the marrow. These mice share all the characteristics of HSC/P transformation in CML, including increased HSC/P proliferation and survival, severely reduced adhesion to fibronectin, increased migration towards CXCL12, increased cell surface expression of CD44 and decreased expression of L-selectin. Myeloproliferative disease (MPD) in these mice is transplantable into recipient mice, and CML splenocytes have a 10-fold increase in homing to the spleen than towards BM (P<0.05). Leukemic splenocytes are also enriched in endosteal lodging progenitors, compared to the BM-derived progenitors (1.9-fold, P≤0.05). In order to determine the contribution of Rac2 GTPase in the transformation phenotype of leukemic stem cells and progenitors, Scl/p210 mice were intercrossed with Rac2-/- mice. Interestingly loss of Rac2 GTPase alone significantly prolongs survival of the leukemic mice (P≤0.001). Prolonged survival, as observed in Scl/p210 x Rac2-/-, is associated with significantly reduced proliferation of leukemic LK (3-fold, P<0.05) and LSK (6-fold P<0.005) cells, both in BM as well as in spleen, in vivo. Scl/p210 x Rac2-/- mice are also characterized by increased apoptosis (1.7-fold) and lower frequency of LSK cells (2-fold) compared to the Scl/p210 mice in vivo. However, deletion of Rac2 does not significantly reverse the adhesion and migration transformation phenotype of LSC/P. In summary, Rac2 deficiency induces a significant survival of CML mice in a HSC-initiated model of disease through decrease proliferation and survival but does not reverse the transformation phenotype affecting adhesion and migration. This murine model may represent an adequate in vivo system to dissect out the specific signaling pathways involved in p210-BCR-ABL-induced stem cell transformation. Disclosures: Cancelas: CERUS CO: Research Funding; CARIDIAN BCT: Research Funding; HEMERUS INC: Research Funding." @default.
• W2562798150 created "2017-01-06" @default.
• W2562798150 creator A5023053157 @default.
• W2562798150 creator A5027506181 @default.
• W2562798150 creator A5073333838 @default.
• W2562798150 creator A5083085571 @default.
• W2562798150 date "2009-11-20" @default.
• W2562798150 modified "2023-10-01" @default.
• W2562798150 title "Deletion of Rac2 inhibits Proliferation of Chronic Myelogenous Leukemia (CML) Stems Cells and Progenitors (HSC/P) In Vivo and Promotes Survival of Scl/p210-BCR-ABL Mice." @default.
• W2562798150 doi "https://doi.org/10.1182/blood.v114.22.3253.3253" @default.
• W2562798150 hasPublicationYear "2009" @default.
• W2562798150 type Work @default.
• W2562798150 sameAs 2562798150 @default.
• W2562798150 citedByCount "1" @default.
• W2562798150 crossrefType "journal-article" @default.
• W2562798150 hasAuthorship W2562798150A5023053157 @default.
• W2562798150 hasAuthorship W2562798150A5027506181 @default.
• W2562798150 hasAuthorship W2562798150A5073333838 @default.
• W2562798150 hasAuthorship W2562798150A5083085571 @default.
• W2562798150 hasConcept C109159458 @default.
• W2562798150 hasConcept C125418893 @default.
• W2562798150 hasConcept C170493617 @default.
• W2562798150 hasConcept C201750760 @default.
• W2562798150 hasConcept C203014093 @default.
• W2562798150 hasConcept C2776960273 @default.
• W2562798150 hasConcept C2777583451 @default.
• W2562798150 hasConcept C2778461978 @default.
• W2562798150 hasConcept C2778729363 @default.
• W2562798150 hasConcept C28328180 @default.
• W2562798150 hasConcept C3019892230 @default.
• W2562798150 hasConcept C42362537 @default.
• W2562798150 hasConcept C43907098 @default.
• W2562798150 hasConcept C502942594 @default.
• W2562798150 hasConcept C54355233 @default.
• W2562798150 hasConcept C62478195 @default.
• W2562798150 hasConcept C86803240 @default.
• W2562798150 hasConcept C95444343 @default.
• W2562798150 hasConceptScore W2562798150C109159458 @default.
• W2562798150 hasConceptScore W2562798150C125418893 @default.
• W2562798150 hasConceptScore W2562798150C170493617 @default.
• W2562798150 hasConceptScore W2562798150C201750760 @default.
• W2562798150 hasConceptScore W2562798150C203014093 @default.
• W2562798150 hasConceptScore W2562798150C2776960273 @default.
• W2562798150 hasConceptScore W2562798150C2777583451 @default.
• W2562798150 hasConceptScore W2562798150C2778461978 @default.
• W2562798150 hasConceptScore W2562798150C2778729363 @default.
• W2562798150 hasConceptScore W2562798150C28328180 @default.
• W2562798150 hasConceptScore W2562798150C3019892230 @default.
• W2562798150 hasConceptScore W2562798150C42362537 @default.
• W2562798150 hasConceptScore W2562798150C43907098 @default.
• W2562798150 hasConceptScore W2562798150C502942594 @default.
• W2562798150 hasConceptScore W2562798150C54355233 @default.
• W2562798150 hasConceptScore W2562798150C62478195 @default.
• W2562798150 hasConceptScore W2562798150C86803240 @default.
• W2562798150 hasConceptScore W2562798150C95444343 @default.
• W2562798150 hasLocation W25627981501 @default.
• W2562798150 hasOpenAccess W2562798150 @default.
• W2562798150 hasPrimaryLocation W25627981501 @default.
• W2562798150 hasRelatedWork W1965619359 @default.
• W2562798150 hasRelatedWork W1992382947 @default.
• W2562798150 hasRelatedWork W2046554377 @default.
• W2562798150 hasRelatedWork W2090527803 @default.
• W2562798150 hasRelatedWork W2150873649 @default.
• W2562798150 hasRelatedWork W2444528506 @default.
• W2562798150 hasRelatedWork W2492610747 @default.
• W2562798150 hasRelatedWork W2557751752 @default.
• W2562798150 hasRelatedWork W2560039739 @default.
• W2562798150 hasRelatedWork W2563555258 @default.
• W2562798150 hasRelatedWork W2564731311 @default.
• W2562798150 hasRelatedWork W2572265095 @default.
• W2562798150 hasRelatedWork W2578264600 @default.
• W2562798150 hasRelatedWork W2585399813 @default.
• W2562798150 hasRelatedWork W2588771628 @default.
• W2562798150 hasRelatedWork W2591368346 @default.
• W2562798150 hasRelatedWork W2980675387 @default.
• W2562798150 hasRelatedWork W3016539526 @default.
• W2562798150 hasRelatedWork W3047237087 @default.
• W2562798150 hasRelatedWork W801242668 @default.
• W2562798150 isParatext "false" @default.
• W2562798150 isRetracted "false" @default.
• W2562798150 magId "2562798150" @default.
• W2562798150 workType "article" @default.